Form 8-K Moderna, Inc. For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Moderna (MRNA) PT Lowered to $120 at Jefferies
August 1, 2024 3:59 PM EDTJefferies analyst Michael Yee lowered the price target on Moderna (NASDAQ: MRNA) to $120.00 (from $180.00) while maintaining a Buy rating.
The analyst comments "Despite confidence YTD, MRNA lowered 2024 guidance by $500M-$1B driven by lower Covid (pricing), APA deferrals + RSV will be small... More
Moderna stock plunges as guidance cut on low EU sales, U.S. vaccine competition
August 1, 2024 6:52 AM EDT(Updated - August 1, 2024 9:51 AM EDT)
Moderna (NASDAQ: MRNA) reported its second-quarter earnings Thursday, revealing a revenue of $241 million, a significant beat compared to the analyst consensus estimate of $128.41 million.
However, the company's stock plummeted by as much as 18% in early Thursday trading due to a downward revision in its full-year revenue guidance.
The biotechnology firm posted an adjusted EPS of -$3.33, narrowly outperforming the analyst estimate of -$3.35. While revenue beat expectations, it marked a 30% decrease from the $344 million reported in the same quarter last... More
